ORIGINAL RESEARCH article

Front. Oncol.

Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1507602

A blood test-based nomogram to predict the progression-free survival of patients with intrahepatic cholangiocarcinoma after surgical resection

Provisionally accepted
  • 1Department of Clinical Laboratory, Hunan Provincial People's Hospital, Changsha, Hunan Province, China
  • 2National Engineering Research Center of Human Stem Cells, Changsha, Hunan Province, China
  • 3Hunan Provincial People's Hospital, Changsha, Hunan Province, China

The final, formatted version of the article will be published soon.

Background: Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy with poor prognosis, and there is currently a lack of effective prognostic prediction models. The aim of this study was to develop a novel nomogram model based on blood tests for predicting predictors of progression free survival (PFS) in ICC patients.Methods: A total of 99 ICC patients (70 for training, 29 for validation) were included in this study. Hematological indices and clinicopathological data were collected from ICC patients undergoing surgical resection. The independent predictors of PFS were screened by univariate and multivariate Cox regression analysis, and a nomogram model was constructed. The calibration curve was used to evaluate the consistency between the observed results and the predicted probability, and the model discrimination was evaluated by receiver operating characteristic curve (ROC). According to the risk score calculated by the constructed nomogram, patients were divided into high-risk and low-risk groups, and the predictive performance of nomogram was further tested by Kaplan Meier.Results: The median follow-up time of this study was 7.8 months (range: 1 ~ 69 months). We found that pathological differentiation, CA19-9, neutrophil-to-lymphocyte ratio (NLR) and after-treatment MON/before-treatment MON (tMON) were independent factors affecting the PFS of postoperative ICC patients. Based on risk factors, a nomogram prediction model was constructed. ROC analysis revealed that the area under the curve (AUC) of the nomogram for predicting PFS was higher than the AJCC-TNM staging system(P<0.05). The calibration curve and DCA showed that the nomogram had high prognostic accuracy and clinical applicability. The risk score calculated by nomogram could divide ICC patients into high-risk and low-risk groups. The median PFS of the high-risk group was significantly shorter than that of the low-risk group (P <0.05). Conclusion: The nomogram can serve as a valuable supplementary tool for predicting PFS in ICC patients after initial surgical resection. Its performance is better than the traditional TNM staging system. The model provides clinicians with an individualized prognostic assessment tool by integrating easily available blood markers, which is helpful to optimize postoperative monitoring and adjuvant treatment strategies.

Keywords: intrahepatic cholangiocarcinoma, Progression free survival, nomogram, blood biomarkers, Prognostic model

Received: 16 Nov 2024; Accepted: 19 May 2025.

Copyright: © 2025 Peng, Shi, Yang and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lirong Peng, Department of Clinical Laboratory, Hunan Provincial People's Hospital, Changsha, 410005, Hunan Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.